UBS AM’s Rubius Therapeutics, Inc RUBY Stock Holding History

UBS AM’s Portfolio RUBY Stock Details RUBY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-30,575	Closed	-$168K	–	2812
2022 Q1	$168K	Hold	30,575	–	–	﹤0.01%	2702
2021 Q4	$296K	Sell	30,575 -1,723	-5%	-$23.9K	﹤0.01%	2679
2021 Q3	$577K	Sell	32,298 -8,281	-20%	-$180K	﹤0.01%	2440
2021 Q2	$991K	Buy	40,579 +15,679	+63%	+$392K	﹤0.01%	2220
2021 Q1	$660K	Buy	24,900 +12,900	+108%	+$188K	﹤0.01%	2285
2020 Q4	$91.1K	Hold	12,000	–	–	﹤0.01%	2537
2020 Q3	$60.1K	Sell	12,000 -9,298	-44%	-$49.2K	﹤0.01%	2476
2020 Q2	$127K	Buy	21,298 +10,998	+107%	+$64.9K	﹤0.01%	2439
2020 Q1	$45.8K	Hold	10,300	–	–	﹤0.01%	2437
2019 Q4	$97.8K	Hold	10,300	–	–	﹤0.01%	2513
2019 Q3	$80.9K	Hold	10,300	–	–	﹤0.01%	2685
2019 Q2	$162K	Buy	+10,300	New	+$166K	﹤0.01%	2590

Other funds holding RUBY

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AFM

Abbot Financial Management Andover, Massachusetts $239M AUM 27.19% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS AM's RUBY Position: Q2 2022 in Review

UBS AM sold out of Rubius Therapeutics, Inc (RUBY) in Q2 2022, closing a stake of 30,575 shares — an estimated $168K sold.

UBS AM first reported a position in RUBY in Q2 2019 and held it in 12 quarters. The position peaked at $991K in Q2 2021. 72 funds tracked by Wall St. Rank hold RUBY as of Q2 2022.

UBS AM reported no remaining Rubius Therapeutics, Inc position as of Q2 2022 after selling out during the quarter.
UBS AM sold 30,575 Rubius Therapeutics, Inc shares in Q2 2022, an estimated $168K.
UBS AM first reported a position in Rubius Therapeutics, Inc in Q2 2019 and held it in 12 quarters.
UBS AM's Rubius Therapeutics, Inc position peaked at $991K in Q2 2021.
72 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q2 2022.

Based on UBS AM's 13F filing for Q2 2022, filed 12 Aug 2022.